Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of subcutaneous MAA868 vs subcutaneous enoxaparin for prevention of venous thromboembolism after unilateral total knee arthroplasty
2017-002925-39Phase 2Terminated
- Sponsor
- Novartis
- Start
- Dec 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of abelacimab in venous thromboembolism (VTE) (2 arms), sponsored by Novartis. Primary endpoints: Composite thromboembolic endpoint and Composite bleeding endpoint. Started Dec 2017; status: terminated.
02
Drugs
abelacimab
03
Conditions
venous thromboembolism (VTE)
Beyond the preview
Go deeper on 2017-002925-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-002925-39.